Overview

Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population subset.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Faes Farma, S.A.